Over the 25 years, Bill has taken up roles of increasing responsibility in Medical Affairs and Clinical Development. Bill moved to
Pfizer HQ, New York in 2004 as Regional Medical Director of Japan/Asia in cardiovascular medicine. In 2009, he became the
Clinical Development Lead of Emerging Markets for medicines in the treatment of heart & thromboembolic diseases, pain,
Alzheimer’s disease, and haemophilia. In 2012, Bill was the Medical Affairs Lead of Asia, leading medical affairs initiatives for
Pfizer’s innovative compound portfolio in internal medicine, inflammation & immunology and rare diseases. In 2017, Bill returned
to Australia to lead the Global Site & Study Operations team who delivers Phase 1-3 global clinical trials in Australia and New
Zealand.
